MDGL Quote, Financials, Valuation and Earnings

Axsome Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -48.92%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Axsome Therapeutics's return on equity of -309.19%.

Madrigal Pharmaceuticals has a consensus price target of $423.14, signalling upside risk potential of 53.73%. On the other hand Axsome Therapeutics has an analysts' consensus of $176.53 which suggests that it could grow by 67.87%. Given that Axsome Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Axsome Therapeutics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Axsome Therapeutics quarterly revenues of $121.5M. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Axsome Therapeutics's net income of -$59.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 18.90x versus 11.75x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

BridgeBio Pharma has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -143.55%. Madrigal Pharmaceuticals's return on equity of -49.57% beat BridgeBio Pharma's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $423.14, signalling upside risk potential of 53.73%. On the other hand BridgeBio Pharma has an analysts' consensus of $58.78 which suggests that it could grow by 71.61%. Given that BridgeBio Pharma has higher upside potential than Madrigal Pharmaceuticals, analysts believe BridgeBio Pharma is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison BridgeBio Pharma has a beta of 1.149, suggesting its more volatile than the S&P 500 by 14.912%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BridgeBio Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. BridgeBio Pharma pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than BridgeBio Pharma quarterly revenues of $116.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than BridgeBio Pharma's net income of -$167.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while BridgeBio Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 18.90x versus 50.78x for BridgeBio Pharma. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of -10220.14%. Madrigal Pharmaceuticals's return on equity of -49.57% beat Cytokinetics's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $423.14, signalling upside risk potential of 53.73%. On the other hand Cytokinetics has an analysts' consensus of $73.45 which suggests that it could grow by 136.78%. Given that Cytokinetics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Cytokinetics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Cytokinetics has a beta of 0.808, suggesting its less volatile than the S&P 500 by 19.173%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Cytokinetics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Cytokinetics quarterly revenues of $1.6M. Madrigal Pharmaceuticals's net income of -$73.2M is higher than Cytokinetics's net income of -$161.4M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Cytokinetics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 18.90x versus 187.05x for Cytokinetics. Usually stocks with elevated PS ratios are considered overvalued.

Viking Therapeutics has a net margin of -53.36% compared to Madrigal Pharmaceuticals's net margin of --. Madrigal Pharmaceuticals's return on equity of -49.57% beat Viking Therapeutics's return on equity of --.

Madrigal Pharmaceuticals has a consensus price target of $423.14, signalling upside risk potential of 53.73%. On the other hand Viking Therapeutics has an analysts' consensus of $90.26 which suggests that it could grow by 236.8%. Given that Viking Therapeutics has higher upside potential than Madrigal Pharmaceuticals, analysts believe Viking Therapeutics is more attractive than Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals has a beta of -0.906, which suggesting that the stock is 190.598% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.754, suggesting its less volatile than the S&P 500 by 24.558%.

Madrigal Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Madrigal Pharmaceuticals pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

Madrigal Pharmaceuticals quarterly revenues are $137.3M, which are larger than Viking Therapeutics quarterly revenues of --. Madrigal Pharmaceuticals's net income of -$73.2M is lower than Viking Therapeutics's net income of -$45.6M. Notably, Madrigal Pharmaceuticals's price-to-earnings ratio is -- while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Madrigal Pharmaceuticals is 18.90x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.